On July 8, 2026, the European Commission published the second and third Joint Clinical Assessment (JCA) reports ever issued under Regulation (EU) 2021/2282 (HTAR), covering two orphan oncology medicines for extensive-stage small cell lung cancer (ES-SCLC): tarlatamab (Imdylltra) and lurbinectedin (Zepzelca). The Commission announced the publication on July 8, 2026, alongside an updated JCA tracker table that now serves as the canonical live view of ongoing assessments. Both reports were endorsed by all Member States on June 22, 2026, and follow the marketing authorisations granted by the Commission on May 29, 2026.
The assessments were carried out by the competent authorities of Germany, Hungary and Portugal under the EU Health Technology Assessment (HTA) Regulation, applicable since January 12, 2025. They follow the first ever JCA report, on tovorafenib (Ojemda), published on June 9, 2026. Two more orphan oncology JCAs in under five weeks signals that the EU joint assessment machine is now operating at a measurable cadence, with direct consequences for national pricing and reimbursement timelines.
What changed on July 8, 2026?
The Commission released two completed JCA reports, one for each medicine, and migrated the official tracking of ongoing assessments to a dedicated Excel-based JCA tracker. The two reports are available as standalone publications: the JCA report on tarlatamab (Imdylltra) and the JCA report on lurbinectedin (Zepzelca). Both are orphan medicinal products for the treatment of extensive-stage small cell lung cancer.
Each report is a shared scientific evaluation of the clinical benefits of the medicine compared to existing treatments, produced collaboratively by appointed national HTA authorities rather than as 27 parallel national assessments. The outputs are not reimbursement decisions: they are reused by every Member State in its national decision on whether to include the medicine in its national health care system.
Who has to use these JCA reports, and by when?
The reports are binding inputs for the national HTA processes of all 27 EU Member States. National HTA bodies such as G-BA (Germany), HAS (France), AIFA (Italy) and AEMPS (Spain) must take the relevant JCA report into account when conducting their national clinical assessments, rather than re-running the full clinical evaluation from scratch. Pricing and reimbursement decisions remain national, so the JCA compresses the clinical-evidence stage of the national pipeline but does not replace the national pricing step.
For the two medicines concerned, manufacturers launching tarlatamab or lurbinectedin in any Member State can now reference a single endorsed EU-level clinical assessment in their national dossiers, instead of submitting 27 separate clinical-evidence packages. The JCA reports also feed the orphan medicinal product JCA track that becomes mandatory for all orphan medicines from January 13, 2028, and for all medicines from January 13, 2030.
How does this fit the HTAR JCA rollout timeline?
| Milestone | Date |
|---|---|
| HTAR applicable (Regulation (EU) 2021/2282) | January 12, 2025 |
| Commission marketing authorisation, tarlatamab and lurbinectedin | May 29, 2026 |
| Endorsement of both JCA reports by all Member States | June 22, 2026 |
| First JCA report ever published (tovorafenib) | June 9, 2026 |
| Second and third JCA reports published (tarlatamab, lurbinectedin) | July 8, 2026 |
| JCA mandatory for orphan medicinal products | January 13, 2028 |
| JCA mandatory for all medicines | January 13, 2030 |
The cadence matters because it sets the learning curve that national HTA bodies and industry are using to refine PICO scoping, evidence packaging and reporting templates before the 2028 orphan expansion increases the volume of JCAs. EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs, has publicly called the first JCA report "a critical milestone" and flagged readiness concerns for orphan products subject to JCA from January 13, 2028, which is exactly the category these two oncology orphans sit in.
What should market access and regulatory leads do now?
Three concrete actions belong on this quarter's agenda. First, download the JCA tracker table and the two published reports, and map your launch portfolio against the ongoing assessments list so your evidence teams can anticipate which of your products will enter the JCA queue next. Second, brief your HEOR and medical teams on the PICO scoping and reporting structure used in these reports, because this format is the de facto template for every subsequent JCA, including the orphan batch that becomes mandatory in 2028. Third, align your national reimbursement dossiers in Germany, France, Italy and Spain to reference the relevant JCA report directly, so your national HTA submissions pick up the EU-level clinical assessment rather than re-deriving it.
A continuous, per-jurisdiction monitoring setup would have surfaced these publications the moment the Commission posted them on July 8, 2026, alongside the tracker update. Obsidian tracks the EU HTAR JCA lineage end to end, from Commission marketing authorisation through Member State endorsement to JCA publication and national HTA reuse, so market access leads do not discover a completed JCA in a competitor's newsletter. Explore how it works on the monitoring page or compare plans on pricing. The AI layer is a verified regulatory companion, not an "expert" or an "analyst": every output is traceable to a primary source.
Download the JCA tracker and both reports, map your launch portfolio against the ongoing assessments queue, and align your national dossiers in Germany, France, Italy and Spain to reference the EU-level JCA directly. Obsidian's monitoring jobs keep the tracker and the source texts current, so the next move is a decision, not a search.